Biogen (BIIB.NASDAQ) and the brain death of big pharma

Ever since the greasy arrogant squirrel-faced grin of Martin Shkreli turned our collective stomach, big pharma has come under fire for their pricing practices. Pharma execs, often paid up to 300 times more than their average employee, shot back that research and development costs were crippling and all that needed to be paid for with healthy profit margins. Should we just buck up and shut up, or are we witnessing the brain death of big pharma?

Equity.Guru podcast: A Closer Look – Rare earth metals miner, Defense Metals (DEFN.V), proving out impressive chemistry at BC property

Rare earth metals were little known before 1960, but in the sixty years since, it has become the foundation for our technologically driven society. You can find rare earth metals in nearly everything electronic from rechargeable batteries to missile guidance systems. There are no substitutes and if there is any supply chain squeezes, the manufacturing of all those convenient and necessary devices that make our life modern, would promptly grind to a halt.